REGAiN-1B: A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Engensis (donaperminogene seltoplasmid) - Beijing Northland, Reyon Pharma, Helixmith

http://clinicaltrials.gov/ct2/show/NCT04873232

Jan 16, 2025